Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: study protocol of the randomized phase II DURATION trial
Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in frail or elderly patients with respect to immunotherapy are lacking. I...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 April 2020
|
| In: |
Trials
Year: 2020, Jahrgang: 21 |
| ISSN: | 1468-6694 |
| DOI: | 10.1186/s13063-020-04280-8 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13063-020-04280-8
|
| Verfasserangaben: | Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Miriam Blasi, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc Schneider and Michael Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1699291802 | ||
| 003 | DE-627 | ||
| 005 | 20230427032040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200603s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-020-04280-8 |2 doi | |
| 035 | |a (DE-627)1699291802 | ||
| 035 | |a (DE-599)KXP1699291802 | ||
| 035 | |a (OCoLC)1341327156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kuon, Jonas |e VerfasserIn |0 (DE-588)1166909484 |0 (DE-627)1030803730 |0 (DE-576)510963129 |4 aut | |
| 245 | 1 | 0 | |a Durvalumab in frail and elderly patients with stage four non-small cell lung cancer |b study protocol of the randomized phase II DURATION trial |c Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Miriam Blasi, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc Schneider and Michael Thomas |
| 264 | 1 | |c 22 April 2020 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.06.2020 | ||
| 520 | |a Elderly patients represent a major fraction of non-small cell lung cancer (NSCLC) patients in routine clinical practice, but they are still underrepresented in clinical trials. In particular, data regarding efficacy and safety in frail or elderly patients with respect to immunotherapy are lacking. Importantly, immunosenescence in elderly patients might interfere with activities of immune-modulating drugs such as PD-1/PD-L1 inhibitors. Thus, there is an urgent need to assess safety and efficacy of such inhibitors in this group. | ||
| 700 | 1 | |a Hommertgen, Adriane |e VerfasserIn |0 (DE-588)1163409006 |0 (DE-627)1027777600 |0 (DE-576)507971353 |4 aut | |
| 700 | 1 | |a Krisam, Johannes |d 1986- |e VerfasserIn |0 (DE-588)1016031343 |0 (DE-627)705475034 |0 (DE-576)351438696 |4 aut | |
| 700 | 1 | |a Lasitschka, Felix |d 1979- |e VerfasserIn |0 (DE-588)140496343 |0 (DE-627)618903542 |0 (DE-576)318526077 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Blasi, Miriam |e VerfasserIn |0 (DE-588)1211411613 |0 (DE-627)1699293422 |4 aut | |
| 700 | 1 | |a Bozorgmehr, Farastuk |d 1979- |e VerfasserIn |0 (DE-588)141921811 |0 (DE-627)632526734 |0 (DE-576)326848150 |4 aut | |
| 700 | 1 | |a Maenz, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kieser, Meinhard |d 1960- |e VerfasserIn |0 (DE-588)103276547X |0 (DE-627)739277766 |0 (DE-576)168963825 |4 aut | |
| 700 | 1 | |a Schneider, Marc |d 1982- |e VerfasserIn |0 (DE-588)140634401 |0 (DE-627)620239948 |0 (DE-576)319208095 |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d London : BioMed Central, 2000 |g 21(2020) Artikel-Nummer 352, 12 Seiten |h Online-Ressource |w (DE-627)326173552 |w (DE-600)2040523-6 |w (DE-576)107014556 |x 1468-6694 |7 nnas |a Durvalumab in frail and elderly patients with stage four non-small cell lung cancer study protocol of the randomized phase II DURATION trial |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g extent:12 |a Durvalumab in frail and elderly patients with stage four non-small cell lung cancer study protocol of the randomized phase II DURATION trial |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13063-020-04280-8 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200603 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 11 |y j | ||
| 998 | |g 140634401 |a Schneider, Marc |m 140634401:Schneider, Marc |d 910000 |d 950000 |d 950900 |e 910000PS140634401 |e 950000PS140634401 |e 950900PS140634401 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 10 | ||
| 998 | |g 103276547X |a Kieser, Meinhard |m 103276547X:Kieser, Meinhard |d 910000 |d 999701 |e 910000PK103276547X |e 999701PK103276547X |k 0/910000/ |k 1/910000/999701/ |p 9 | ||
| 998 | |g 141921811 |a Bozorgmehr, Farastuk |m 141921811:Bozorgmehr, Farastuk |d 910000 |d 950000 |d 950900 |e 910000PB141921811 |e 950000PB141921811 |e 950900PB141921811 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 7 | ||
| 998 | |g 1211411613 |a Blasi, Miriam |m 1211411613:Blasi, Miriam |d 910000 |d 950000 |d 950900 |e 910000PB1211411613 |e 950000PB1211411613 |e 950900PB1211411613 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 6 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 5 | ||
| 998 | |g 140496343 |a Lasitschka, Felix |m 140496343:Lasitschka, Felix |p 4 | ||
| 998 | |g 1016031343 |a Krisam, Johannes |m 1016031343:Krisam, Johannes |d 910000 |d 999701 |e 910000PK1016031343 |e 999701PK1016031343 |k 0/910000/ |k 1/910000/999701/ |p 3 | ||
| 998 | |g 1163409006 |a Hommertgen, Adriane |m 1163409006:Hommertgen, Adriane |d 910000 |d 911400 |e 910000PH1163409006 |e 911400PH1163409006 |k 0/910000/ |k 1/910000/911400/ |p 2 | ||
| 998 | |g 1166909484 |a Kuon, Jonas |m 1166909484:Kuon, Jonas |d 910000 |d 950000 |d 950900 |e 910000PK1166909484 |e 950000PK1166909484 |e 950900PK1166909484 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1699291802 |e 3681756031 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"22 April 2020","dateIssuedKey":"2020"}],"person":[{"family":"Kuon","role":"aut","display":"Kuon, Jonas","given":"Jonas"},{"family":"Hommertgen","role":"aut","display":"Hommertgen, Adriane","given":"Adriane"},{"family":"Krisam","role":"aut","display":"Krisam, Johannes","given":"Johannes"},{"display":"Lasitschka, Felix","role":"aut","family":"Lasitschka","given":"Felix"},{"given":"Albrecht","display":"Stenzinger, Albrecht","role":"aut","family":"Stenzinger"},{"role":"aut","display":"Blasi, Miriam","family":"Blasi","given":"Miriam"},{"family":"Bozorgmehr","display":"Bozorgmehr, Farastuk","role":"aut","given":"Farastuk"},{"display":"Maenz, Martin","role":"aut","family":"Maenz","given":"Martin"},{"given":"Meinhard","role":"aut","display":"Kieser, Meinhard","family":"Kieser"},{"given":"Marc","display":"Schneider, Marc","role":"aut","family":"Schneider"},{"display":"Thomas, Michael","role":"aut","family":"Thomas","given":"Michael"}],"id":{"eki":["1699291802"],"doi":["10.1186/s13063-020-04280-8"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Durvalumab in frail and elderly patients with stage four non-small cell lung cancer","title_sort":"Durvalumab in frail and elderly patients with stage four non-small cell lung cancer","subtitle":"study protocol of the randomized phase II DURATION trial"}],"name":{"displayForm":["Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Miriam Blasi, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc Schneider and Michael Thomas"]},"recId":"1699291802","physDesc":[{"extent":"12 S."}],"relHost":[{"pubHistory":["1.2000 -"],"language":["eng"],"origin":[{"publisher":"BioMed Central","dateIssuedKey":"2000","publisherPlace":"London","dateIssuedDisp":"2000-"}],"id":{"zdb":["2040523-6"],"issn":["1468-6694","1745-6215"],"eki":["326173552"]},"part":{"text":"21(2020) Artikel-Nummer 352, 12 Seiten","year":"2020","volume":"21","extent":"12"},"disp":"Durvalumab in frail and elderly patients with stage four non-small cell lung cancer study protocol of the randomized phase II DURATION trialTrials","title":[{"title":"Trials","title_sort":"Trials"}],"recId":"326173552","physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 26.09.22"],"titleAlt":[{"title":"Current controlled trials in cardiovascular medicine"}],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Gesehen am 03.06.2020"],"language":["eng"]} | ||
| SRT | |a KUONJONASHDURVALUMAB2220 | ||